Potential health effects from non-specific stimulation of the immune function in early age: The example of BCG vaccination
Marie-Claude Rousseau
INRS-Institut Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Laval, QC, Canada
Search for more papers by this authorMarie-Elise Parent
INRS-Institut Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Laval, QC, Canada
Search for more papers by this authorYves St-Pierre
INRS-Institut Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Laval, QC, Canada
Search for more papers by this authorMarie-Claude Rousseau
INRS-Institut Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Laval, QC, Canada
Search for more papers by this authorMarie-Elise Parent
INRS-Institut Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Laval, QC, Canada
Search for more papers by this authorYves St-Pierre
INRS-Institut Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Laval, QC, Canada
Search for more papers by this authorAbstract
There is increasing, but still inconsistent evidence that vaccinations and childhood infections may play a role in the normal maturation of the immune system, and in the development and balance of immune regulatory pathways, both of which might impact health later in life. This review covers the epidemiological evidence regarding the role of Bacillus Calmette–Guérin (BCG) vaccination on the following inflammatory or autoimmune diseases: asthma and allergic diseases, Crohn’s disease (CD), insulin-dependent diabetes mellitus (IDDM), and specific cancers. The literature is more comprehensive for asthma and allergic diseases, with 16 studies reporting the absence of an association while seven rather suggest a protective effect of BCG. We found insufficient evidence on CD to conclude at this point. Overall, the evidence for IDDM based on four studies leans towards no association, although some effects were observed in population subsets. Five epidemiological investigations provide evidence on a possible link with cancer incidence or mortality at various sites, with indications of both increased and decreased risks. Given the potential public health implications, it is imperative to acquire a better understanding of how BCG vaccination could influence the development of such chronic health conditions in the population.
References
- 1 Mitsuyasu RT. AIDS-related Kaposi’s sarcoma: current treatment options, future trends. Oncology (Williston Park) 2000: 14: 867–78; discussion on 878, 881–3,887.
- 2 Palefsky JM, Holly EA. Chapter 6: immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 2003: 31: 41–6.
- 3 Kopf S, Tonshoff B. Adenotonsillar hypertrophy and post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatr Nephrol 2004: 19: 471–2.
- 4 Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989: 7: 145–73.
- 5 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002: 420: 860–7.
- 6 Libby P. Inflammation in atherosclerosis. Nature 2002: 420: 868–74.
- 7 Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004: 25: 477–82.
- 8 Cohn L. Mucus in chronic airway diseases: sorting out the sticky details. J Clin Invest 2006: 116: 306–8.
- 9 Umetsu DT, Akbari O, Dekruyff RH. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003: 112: 480–7; quiz 488.
- 10 Zhang X, Koldzic DN, Izikson L, et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+regulatory T cells. Int Immunol 2004: 16: 249–56.
- 11 Yabuhara A, Macaubas C, Prescott SL, et al. TH2-polarized immunological memory to inhalant allergens in atopics is established during infancy and early childhood. Clin Exp Allergy 1997: 27: 1261–9.
- 12 Kemp A, Björkstén B. Immune deviation and the hygiene hypothesis: a review of the epidemiological evidence. Pediatr Allergy Immunol 2003: 14: 74–80.
- 13 Dahl ME, Dabbagh K, Liggitt D, Kim S, Lewis DB. Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells. Nat Immunol 2004: 5: 337–43.
- 14 Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004: 112: 352–63.
- 15 Scanga CB, Le Gros G. Development of an asthma vaccine: research into BCG. Drugs 2000: 59: 1217–21.
- 16 Malmstrom PU, Wijkstrom H, Lundholm C, et al. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette–Guerin in patients with superficial bladder carcinoma. Swedish–Norwegian Bladder Cancer Study Group. J Urol 1999: 161: 1124–7.
- 17 Huber CH, Wölfel T. Immmunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004: 130: 367–74.
- 18 Suttmann H, Jacobsen M, Reiss K, et al. Mechanisms of bacillus Calmette–Guerin mediated natural killer cell activation. J Urol 2004: 172: 1490–5.
- 19 Sander B, Skansen-Saphir U, Damm O, et al. Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette–Guerin. Immunology 1995: 86: 512–8.
- 20 Herz U, Gerhold K, Grüber C, et al. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol 1998: 102: 867–74.
- 21 Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G. Infection of mice with Mycobacterium bovis–Bacillus Calmette–Guerin (BCG) suppresses allergen-induced airway eosinophilia. J Exp Med 1998: 187: 561–9.
- 22 Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998: 93: 307–13.
- 23 Tukenmez F, Bahceciler NN, Barlan IB, Basaran MM. Effect of pre-immunization by killed Mycobacterium bovis and vaccae on immunoglobulin E response in ovalbumin-sensitized newborn mice. Pediatr Allergy Immunol 1999: 10: 107–11.
- 24 Ozdemir C, Akkoc T, Bahceciler NN, et al. Impact of Mycobacterium vaccae immunization on lung histopathology in a murine model of chronic asthma. Clin Exp Allergy 2003: 33: 266–70.
- 25 Delgado JC, Tsai EY, Thim S, et al. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci U S A 2002: 99: 7576–81.
- 26 Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998: 102: 98–106.
- 27 Hawrylowicz C, Richards D, Loke TK, Corrigan C, Lee T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J Allergy Clin Immunol 2002: 109: 369–70.
- 28 Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006: 173: 803–10.
- 29 Hawrylowicz CM, O’Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005: 5: 271–83.
- 30 Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002: 2: 46–53.
- 31 Gojova A, Brun V, Esposito B, et al. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003: 102: 4052–8.
- 32 Piccirillo CA, Letterio JJ, Thornton AM, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 2002: 196: 237–46.
- 33 Scherf W, Burdach S, Hansen G. Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model. Eur J Immunol 2005: 35: 198–206.
- 34 Illi S, Von Mutius E, Lau S, et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ 2001: 322: 390–5.
- 35 Nickel R, Lau S, Niggemann B, et al. Messages from the German Multicentre Allergy Study. Pediatr Allergy Immunol 2002: 13: 7–10.
- 36 Ball TM, Castro-Rodriguez JA, Griffith KA, et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 2000: 343: 538–43.
- 37 Infante-Rivard C, Fortier I, Olson E. Markers of infection, breast-feeding and childhood acute lymphoblastic leukaemia. Br J Cancer 2000: 83: 1559–64.
- 38 Alm JS, Lilja G, Pershagen G, Scheynius A. Early BCG vaccination and development of atopy. Lancet 1997: 350: 400–3.
- 39 Omenaas E, Jentoft HF, Vollmer WM, Buist AS, Gulsvik A. Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults. Thorax 2000: 55: 454–8.
- 40 Yilmaz M, Bingol G, Altintas D, Kendirli SG. Correlation between atopic diseases and tuberculin responses. Allergy 2000: 55: 664–7.
- 41 Grüber C, Kulig M, Bergmann R, Guggenmoos-Holzmann I, Wahn U. Delayed hypersensitivity to tuberculin, total immunoglobulin E, specific sensitization, and atopic manifestation in longitudinally followed early Bacille Calmette–Guerin-vaccinated and nonvaccinated children. Pediatrics 2001: 107: E36.
- 42 Anderson HR, Poloniecki JD, Strachan DP, et al. Immunization and symptoms of atopic disease in children: results from the International Study of Asthma and Allergies in Childhood. Am J Public Health 2001: 91: 1126–9.
- 43 Wong GW, Hui DS, Tam CM, et al. Asthma, atopy and tuberculin responses in Chinese schoolchildren in Hong Kong. Thorax 2001: 56: 770–3.
- 44 Jentoft HF, Omenaas E, Eide GE, Gulsvik A. Absence of relationship between tuberculin reactivity and asthmatic symptoms, level of FEV1 and bronchial hyperresponsiveness in BCG vaccinated young adults. Allergy 2002: 57: 336–40.
- 45 Pahari A, Welch S, Lingam S. BCG, tuberculin skin-test results and asthma prevalence in school children in North London. Indian Pediatr 2002: 39: 254–8.
- 46 Krause TG, Hviid A, Koch A, et al. BCG vaccination and risk of atopy. JAMA 2003: 289: 1012–5.
- 47 Ota MO, Van Der Sande MA, Walraven GE, et al. Absence of association between delayed type hypersensitivity to tuberculin and atopy in children in The Gambia. Clin Exp Allergy 2003: 33: 731–6.
- 48 Strannegard IL, Larsson LO, Wennergren G, Strannegard O. Prevalence of allergy in children in relation to prior BCG vaccination and infection with atypical mycobacteria. Allergy 1998: 53: 249–54.
- 49 Grüber C, Meinlschmidt G, Bergmann R, Wahn U, Stark K. Is early BCG vaccination associated with less atopic disease? An epidemiological study in German preschool children with different ethnic backgrounds. Pediatr Allergy Immunol 2002: 13: 177–81.
- 50 Marks GB, Ng K, Zhou J, et al. The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: an historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease. J Allergy Clin Immunol 2003: 111: 541–9.
- 51 Annus T, Montgomery SM, Riikjarv MA, Björkstén B. Atopic disorders among Estonian schoolchildren in relation to tuberculin reactivity and the age at BCG vaccination. Allergy 2004: 59: 1068–73.
- 52 Townley RG, Barlan IB, Patino C, et al. The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children. Ann Allergy Asthma Immunol 2004: 92: 350–5.
- 53 Da Cunha SS, Cruz AA, Dourado I, et al. Lower prevalence of reported asthma in adolescents with symptoms of rhinitis that received neonatal BCG. Allergy 2004: 59: 857–62.
- 54 Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997: 275: 77–9.
- 55 Aaby P, Shaheen SO, Heyes CB, et al. Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin Exp Allergy 2000: 30: 644–50.
- 56 Sarinho E, Schor D, Veloso M, Lima M. BCG scar diameter and asthma: a case–control study. J Allergy Clin Immunol 2000: 106: 1199–200.
- 57 Bager P, Rostgaard K, Nielsen NM, Melbye M, Westergaard T. Age at bacille Calmette–Guerin vaccination and risk of allergy and asthma. Clin Exp Allergy 2003: 33: 1512–7.
- 58 Garcia-Marcos L, Suarez-Varela MM, Canflanca IM, et al. BCG immunization at birth and atopic diseases in a homogeneous population of Spanish schoolchildren. Int Arch Allergy Immunol 2005: 137: 303–9.
- 59 Martignon G, Oryszczyn MP, Annesi-Maesano I. Does childhood immunization against infectious diseases protect from the development of atopic disease? Pediatr Allergy Immunol 2005: 16: 193–200.
- 60 Obihara CC, Beyers N, Gie RP, et al. Inverse association between Mycobacterium tuberculosis infection and atopic rhinitis in children. Allergy 2005: 60: 1121–5.
- 61 Von Hertzen LC, Haahtela T. Immunization and atopy: possible implications of ethnicity. J Allergy Clin Immunol 2004: 113: 401–6.
- 62 Krishna MT, Salvi SS. Could administration of bacille Calmette–Guerin vaccination at birth protect from the development of asthma and allergic diseases in the western world? Has this question been adequately investigated? Pediatr Allergy Immunol 2002: 13: 172–6.
- 63 Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996: 379: 821–3.
- 64 Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001: 411: 599–603.
- 65 Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet 2006: 367: 668–78.
- 66 Greenstein RJ. Is Crohn’s disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne’s disease. Lancet Infect Dis 2003: 3: 507–14.
- 67 Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994: 343: 766–7.
- 68 Duggan AE, Usmani I, Neal KR, Logan RF. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut 1998: 43: 494–8.
- 69 Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn’s disease. An international cooperative study. Scand J Gastroenterol 1987: 22: 1009–24.
- 70 Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case–control study. Am J Epidemiol 1990: 132: 1111–9.
- 71 Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994: 39: 555–60.
- 72 Amre DK, Lambrette P, Law L, et al. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn’s disease: a case–control study. Am J Gastroenterol 2006: 101: 1005–11.
- 73 Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn’s disease. Immunol Rev 2005: 206: 277–95.
- 74 Wells RW, Blennerhassett MG. The increasing prevalence of Crohn’s disease in industrialized societies: the price of progress? Can J Gastroenterol 2005: 19: 89–95.
- 75 Collins MT, Lisby G, Moser C, et al. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol 2000: 38: 4373–81.
- 76 Baron S, Turck D, Leplat C, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005: 54: 357–63.
- 77 Silva DG, Charlton B, Cowden W, Petrovsky N. Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen. Ann N Y Acad Sci 2003: 1005: 423–30.
- 78 Toyota T, Satoh J, Oya K, Shintani S, Okano T. Streptococcal preparation (OK-432) inhibits development of type I diabetes in NOD mice. Diabetes 1986: 35: 496–9.
- 79 McInerney MF, Pek SB, Thomas DW. Prevention of insulitis and diabetes onset by treatment with complete Freund’s adjuvant in NOD mice. Diabetes 1991: 40: 715–25.
- 80 Sadelain MW, Qin HY, Lauzon J, Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990: 39: 583–9.
- 81 Sadelain MW, Qin HY, Sumoski W, et al. Prevention of diabetes in the BB rat by early immunotherapy using Freund’s adjuvant. J Autoimmun 1990: 3: 671–80.
- 82 Qin HY, Singh B. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J Autoimmun 1997: 10: 271–8.
- 83 Harada M, Kishimoto Y, Makino S. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res Clin Pract 1990: 8: 85–9.
- 84 Classen DC, Classen J.B. The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. Infect Dis Clin Pract 1997: 6: 449–54.
- 85 Parent ME, Siemiatycki J, Menzies R, Fritschi L, Colle E. Bacille Calmette–Guerin vaccination and incidence of IDDM in Montreal, Canada. Diabetes Care 1997: 20: 767–72.
- 86 Huppmann M, Baumgarten A, Ziegler AG, Bonifacio E. Neonatal Bacille Calmette–Guerin vaccination and type 1 diabetes. Diabetes Care 2005: 28: 1204–6.
- 87 Sanjeevi CB, Das AK, Shtauvere-Brameus A. BCG vaccination and GAD65 and IA-2 autoantibodies in autoimmune diabetes in southern India. Ann N Y Acad Sci 2002: 958: 293–6.
- 88 IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk to Humans, Vol. 59. Hepatitis Viruses. Lyon: IARC, 1994.
- 89 IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk to Humans, Vol. 61. Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: IARC, 1994.
- 90 Thomas L. In: Cellular and humoral aspects of hypersensitivity states. HS Lawrence, ed. New York: (Hoeber), Harper, 1959: 451–68.
- 91 Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst 1979: 62: 353–8.
- 92 Hoover R, Fraumeni JF Jr. Risk of cancer in renal-transplant recipients. Lancet 1973: 2: 55–7.
- 93 Kinlen LJ, Clarke K, Hudson C. Evidence from population mixing in British New Towns 1946–85 of an infective basis for childhood leukaemia. Lancet 1990: 336: 577–82.
- 94 Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001: 410: 1107–11.
- 95 Tavani A, La Vecchia C, Franceschi S, Serraino D, Carbone A. Medical history and risk of Hodgkin’s and non-Hodgkin’s lymphomas. Eur J Cancer Prev 2000: 9: 59–64.
- 96 Hjalgrim H, Askling J, Sorensen P, et al. Risk of Hodgkin’s disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 2000: 92: 1522–8.
- 97 Hjalgrim H, Rostgaard K, Askling J, et al. Hematopoietic and lymphatic cancers in relatives of patients with infectious mononucleosis. J Natl Cancer Inst 2002: 94: 678–81.
- 98 Chang ET, Zheng T, Weir EG, et al. Childhood social environment and Hodgkin’s lymphoma: new findings from a population-based case–control study. Cancer Epidemiol Biomarkers Prev 2004: 13: 1361–70.
- 99 Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006: 6: 193–203.
- 100 Davignon L, Robillard P, Lemonde P, Frappier A. B.C.G. vaccination and leukemia mortality. Lancet 1970: 2: 638.
- 101 Davignon L, Lemonde P, St-Pierre J, Frappier A. B.C.G. vaccination and leukaemia mortality. Lancet 1971: 1: 80–1.
- 102 Stewart AM, Draper GJ. B.C.G. vaccination and leukaemia mortality. Lancet 1970: 2: 983–4.
- 103 Pike MC, Vessey MP. B.C.G. vaccination and leukaemia mortality. Lancet 1970: 2: 983–4.
- 104 Waaler HT. B.C.G. and leukaemia mortality. Lancet 1970: 2: 1314.
- 105 Hems G, Stuart A. B.C.G. and leukaemia. Lancet 1971: 1: 183.
- 106 Grange JM, Stanford JL. BCG vaccination and cancer. Tubercle 1990: 71: 61–4.
- 107 Snider DE, Comstock GW, Martinez I, Caras GJ. Efficacy of BCG vaccination in prevention of cancer: an update. J Natl Cancer Inst 1978: 60: 785–8.
- 108 Kendrick MA, Comstock GW. BCG vaccination and the subsequent development of cancer in humans. J Natl Cancer Inst 1981: 66: 431–7.
- 109 Grange JM, Stanford JL, Stanford CA, Kölmel KF. Vaccination strategies to reduce the risk of leukaemia and melanoma. J R Soc Med 2003: 96: 389–92.
- 110 Krone B, Kölmel KF, Grange JM, et al. Impact of vaccinations and infectious diseases on the risk of melanoma—evaluation of an EORTC case–control study. Eur J Cancer 2003: 39: 2372–8.
- 111 Pfahlberg A, Kölmel KF, Grange JM, et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J Invest Dermatol 2002: 119: 570–5.
- 112 Kölmel KF, Grange JM, Krone B, et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 2005: 41: 118–25.
- 113 Rosenthal SR. Cancer precursors and their control by BCG. Dev Biol Stand 1986: 58 (Pt A): 401–16.
- 114 Dahlquist G, Gothefors L. The cumulative incidence of childhood diabetes mellitus in Sweden unaffected by BCG-vaccination. Diabetologia 1995: 38: 873–4.